Since its commercialization in France in 1987, rimantadine has been used to prevent influenza when administered to people (health professionals or family members) in contact with ill individuals during influenza A virus epidemics (1) . The emergence and possible transmission of rimantadineresistant strains during combined therapeutic and prophylactic use of the drug in the United States during the 1987 and 1988 outbreak (2) or the 1988 and 1989 outbreak (10) led us to develop a test to evaluate the rimantadine susceptibilities of influenza A isolates. The present study focused on the strains isolated during the epidemic in the winter of 1988 (A/HlN1 subtype) and the epidemic in the winter of 1989 (A/IH3N2 subtype). Rimantadine-resistant strains were obtained from World Health Organization's Influenza Center, National Institute for Medical Research, London, United Kingdom (3, 10) .
An overnight enzyme-linked immunosorbent assay (ELISA) for detection of viral antigens was used, with modifications (2, 11). Vero or MDCK cells were grown on microtiter plates. Each virus stock was tested in serial dilutions ranging from 10-1 to 10' against six rimantadine concentrations (rimantadine was kindly provided by Roche Laboratories) ranging from 40 to 0.0026 ,g/ml in fivefold dilutions (7) (8) (9) . We also screened the A/HlN1 isolates at concentrations ranging from 5 to 0.002 ,ug/ml in fourfold dilutions. The plates were centrifuged at 225 x g. Each test was performed in duplicate wells, and cell controls were included on each plate to evaluate the cellular toxicity of the antiviral agent (6) .
Cells were fixed with 0.1% glutaraldehyde and were then incubated with a rabbit antiserum to either A/Guizhou/54/89-like (A/H3N2) or A/Singapore/6/86-like (A/H1N1) viruses. We used a protein A-horseradish peroxidase conjugate (BioRad Laboratories, Richmond, Calif.), and the substrate was a 2,2-azino-di(3-ethylbenzthiazoline) sulfonic acid (ABTS; Zymed Laboratories, San Francisco, Calif.) in ABTS buffer (Boehringer, Mannheim, Germany). After agitation for a short period of time, the optical densities at 405 nm were * Corresponding author.
read by using a multichannel spectrophotometer (TitertekMultiskan), and all the data were analyzed in a microcomputer.
In our assay, we used a chessboard titration technique that allowed simultaneous titration of the virus both in the absence and in the presence of increasing rimantadine doses. The ELISA was performed after 20 h of virus multiplication on MDCK cells and 44 h of virus multiplication on Vero cells to allow for sufficient virus multiplication.
The virus titer was the inverse value of the dilution producing 50% antigenic material. This titer was calculated by the geometrical method from the two points nearest the 50% value. The rimantadine concentration giving a 50% reduction in the production of antigenic material (EC5O) was evaluated at the optimal viral dilution.
In vitro testing of A/H3N2 strains. The vaccine prototype strains were tested on the two continuous cell lines. With Vero cells, the infectious titer of A/Shanghai/16/89 was 104-3, which was 1 dilution higher than the titer observed with MDCK cells, but the susceptibility to rimantadine was comparable in MDCK cells (EC50, 0.018 ,ug/ml) and Vero cells (EC50, 0.03 ,ug/ml) at the optimal virus dilution. The strain A/Guizhou/54/89 reached a similar infectious titer (104) and also showed the same susceptibility (EC50, 0.01 ,ug/ml) for both cell lines. For the A/Lyon/5389/88 strain, the rimantadine EC50 was 0.03 ±g/ml in MDCK cells. For the resistant control strain A/New York/83/R6, EC50s were 21 pg/ml in Vero cells and 27 ,ug/ml in MDCK cells. For other isolates from the two studies (3, 10) tested in MDCK cells, EC50s ranged from 4 to 14 Fg/ml (P was not significant) in the first group and from 9 to 14 ,ug/ml (P was not significant) in the second group (Table 1) .
The relationship between the growth ability of influenza viruses on two continuous cell lines and the rimantadine EC50 was tested on 10 clinical isolates. In Vero cells the titer was an average of 102-9, but the same isolates grew to nearly 100-fold higher titers in MDCK cells. The by our assay and the amino acid changes in the M2 protein.
All the influenza virus A isolates tested in the present study were susceptible to the antiviral action of rimantadine, but none of the patients was in contact or undergoing treatment with rimantadine. In France, prescription of rimantadine for the prevention of influenza virus A is restricted to those who are in contact with a patient with influenzalike illness during documented periods of virus activity in the community. Results of the present study confirm the results of previous studies, showing that naturally occurring strains of influenza virus A are uniformly susceptible to rimantadine (2, 3, 5) .
